Overview

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Status:
Terminated

Trial end date:
2016-08-17

Target enrollment:

Participant gender:

Summary

Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with fludarabine/treosulfan

Phase:

Phase 2

Details

Lead Sponsor:

Prof. Dr. med. Wolfgang Bethge

Collaborators:

medac GmbH
Neovii Biotech
Pfizer

Treatments:

Fludarabine
Mycophenolate mofetil
Mycophenolic Acid
Treosulfan